A cost-effectiveness analysis of adjuvant therapies for resected adenocarcinoma of the rectum.

被引：0
|
作者：
Lee, JH [1 ]
机构：
[1] UNIV PENN,SCH MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 39卷 / 02期
关键词：
D O I：
10.1016/S0360-3016(97)80759-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [1] Adjuvant FOLFIRINOX in Patients with Resected Pancreatic Ductal Adenocarcinoma: A Cost-effectiveness Analysis
    Hersh, A. R.
    Buuck, T.
    Wagner, J.
    Kardosh, A.
    Caughey, A.
    Mayo, S. C.
    Billingsley, K. G.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S45 - S45
  • [2] A cost-effectiveness analysis of adjuvant chemoradiation therapy following surgery for gastric adenocarcinoma
    Wang, SJ
    Joyner, MM
    Kachnic, LA
    Thomas, CR
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S116 - S116
  • [3] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RESECTED STAGE IIB/IIC MELANOMA IN GREECE
    Yfantopoulos, N.
    Spanoudi, F.
    Draganigos, A.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [4] A cost-effectiveness analysis of oral triptan therapies
    Yalkowsky, RB
    Malone, DC
    VALUE IN HEALTH, 2002, 5 (06) : 455 - 455
  • [5] Cost-effectiveness analysis of current therapies for melasma
    Piacquadio, DJ
    Smith, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P175 - P175
  • [6] Cost-effectiveness of adjuvant chemotherapy in resected non-small cell cancer
    Messori, Andrea
    Caccese, Erminia
    Cecchi, Michele
    Orsi, Cecilia
    Tendi, Enrico
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 486 - 486
  • [7] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
    Shujing Zhang
    Arielle G. Bensimon
    Ruifeng Xu
    Ruixuan Jiang
    Alexandra Greatsinger
    Adina Zhang
    Mizuho Fukunaga-Kalabis
    Clemens Krepler
    Advances in Therapy, 2023, 40 : 3038 - 3055
  • [8] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
    Zhang, Shujing
    Bensimon, Arielle G.
    Xu, Ruifeng
    Jiang, Ruixuan
    Greatsinger, Alexandra
    Zhang, Adina
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    ADVANCES IN THERAPY, 2023, 40 (07) : 3038 - 3055
  • [9] A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
    Casabianca, Paul
    Massetti, Marc
    Cotte, Francois-Emery
    Moreau, Romain
    Kassahun, Sarah
    Singh, Prianka
    Kim, Inkyu
    Gaudin, Anne-Francoise
    Piessen, Guillaume
    Leleu, Henri
    PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 689 - 699
  • [10] A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1373 - 1379
12345